Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.
When Providers Don't Use Gender-Affirming Language, It Negatively Impacts HIV-Positive Transgender Women's Health
A new study shows that helping clinicians use gender-affirming language is important for transgender women in care. But we need more research on how HIV medications and feminizing hormones interact.
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
The new public-private partnership will put $200 million toward finding eventual cures for two of the world's most pervasive diseases.
Oct. 24, 2019: A computerized antiretroviral recommendation tool; higher Fiebig stage equals more frequent viral load blips; low prescription refill rates among Americans starting treatment; internalized stigma and HIV outcomes.
Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.
We walk you through the most recent updates to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV.
This population is under-represented in HIV data, and few prevention or treatment interventions exist to support them. A new meta-analysis hopes to paint a picture of what's needed.
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.